Longevity, genes,
and disease-modifying AI.

Prime Medicine PM647: FDA clears IND for in vivo Prime Editing in alpha-1 antitrypsin deficiency (2026-09-24)

A one-time IV Prime Editor designed to correct the SERPINA1 E342K (Pi*Z) mutation, targeting both lung and liver disease rather than protein replacement alone. Global Phase 1/2 first-in-human study: lung-only cohort first, liver cohort after tolerability. Initial data expected 2027. Uses the same liver LNP as PM577a (Wilson disease).

Caveat: IND clearance is not approval. Investigational, open-label, early phase; no human efficacy data yet.

Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence (Signal Transduction and Targeted Therapy, 2026-09-23)

Bone-marrow Tregs transfer cAMP to aged HSCs, activating PKA-CREB and then BIRC6, which gives aged HSCs a survival advantage and myeloid-biased, immunosenescent output. CD117-targeted LNP-ASOs against BIRC6 reversed HSC aging traits, rebalanced lymphoid output, lowered inflammatory markers, and raised Spike-vaccine antibody titers about 22-fold in middle-aged mice. Middle-aged human HSCs showed similar BIRC6 upregulation and ex vivo ASO effects.

Caveat: Preclinical and ex vivo human cells only. Not a clinical therapy, no human in vivo dosing, and not a lifespan claim.

Nature Aging: Neisseria flavescens identified as a central geroprotective oral commensal (2026-09-24)

AI multi-modality aging clocks (AURORA) plus the human oral metagenome and metabolome linked N. flavescens with slower aging. Live Nf extended C. elegans lifespan and healthspan; heat-killed Nf in aged mice shifted the serum metabolome, liver transcriptome, and gut microbiome toward younger states. The authors flag the oral microbiome as an under-studied area for geroprotection.

Caveat: Association plus animal validation, with a patent pending on Nf uses. Not a human probiotic recommendation or an anti-aging drug.

DNA methylation signatures of cellular senescence are not reversed by senolytic treatment (Aging Cell)

Only about 2.4% of CpGs line up across senescence, age, and mortality. Three senescence-enriched DNAm clocks (SenCultureAge, SenChronoAge, SenMortalityAge) stayed the same or sped up after senolytics in vitro and in vivo, including dasatinib plus quercetin — challenging the use of DNAm clocks as endpoints for senolytic rejuvenation.

Caveat: A biomarker study. It doesn’t prove senolytics fail clinically, and clocks are not clinical outcomes.

Neuron: Genome-wide in vivo CRISPRi maps cell-type- and age-dependent neuronal vulnerability (online 2026-09-09)

Scalable CRISPRi in mouse brain across four neuronal populations and three ages, from youth to aging, yielded 269 consensus neuronal essential genes and cell-type-specific vulnerabilities (e.g., Exosc9, Ostm1). It also found aging-enriched mitochondrial and translational dependencies that match human brain aging transcripts. Community portal: CRISPRinvivo.

Caveat: Mouse functional genomics, not a therapy. The link to humans is correlative.

Research AI ≠ clinical cure claims

An IND clearance, mouse and ex vivo stem-cell work, an association study with animal validation, a biomarker analysis, and a mouse functional-genomics screen are different evidence classes. This site keeps them labeled so a headline never collapses into “AI cured aging.”